PE20121481A1 - Formulacion de liberacion sostenida - Google Patents
Formulacion de liberacion sostenidaInfo
- Publication number
- PE20121481A1 PE20121481A1 PE2012000862A PE2012000862A PE20121481A1 PE 20121481 A1 PE20121481 A1 PE 20121481A1 PE 2012000862 A PE2012000862 A PE 2012000862A PE 2012000862 A PE2012000862 A PE 2012000862A PE 20121481 A1 PE20121481 A1 PE 20121481A1
- Authority
- PE
- Peru
- Prior art keywords
- sustained release
- release formulation
- refers
- glycolic acid
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE LIBERACION SOSTENIDA QUE COMPRENDE: A) UN COMPUESTO DERIVADO DE METASTINA DE FORMULA (I) QUE ES Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 O UNA SAL DEL MISMO; Y B) UN COPOLIMERO DE ACIDO LACTICO-ACIDO GLICOLICO QUE TIENE UN PESO MOLECULAR DE 5000 A 40000, EN DONDE EL CONTENIDO DEL ACIDO GLICOLICO ES DE 0% A 60% EN PESO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHA FORMULACION ES UN AGENTE PARENTERAL UTIL EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009290364 | 2009-12-22 | ||
JP2010144793 | 2010-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121481A1 true PE20121481A1 (es) | 2012-11-12 |
Family
ID=43743497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000862A PE20121481A1 (es) | 2009-12-22 | 2010-12-21 | Formulacion de liberacion sostenida |
Country Status (26)
Country | Link |
---|---|
US (2) | US20120302508A1 (es) |
EP (1) | EP2515878B1 (es) |
JP (3) | JP2013514968A (es) |
KR (1) | KR20120098906A (es) |
CN (2) | CN107412725A (es) |
AR (1) | AR079657A1 (es) |
AU (1) | AU2010336168A1 (es) |
BR (1) | BR112012014947A2 (es) |
CA (1) | CA2785021C (es) |
CO (1) | CO6551752A2 (es) |
CR (1) | CR20120290A (es) |
DO (1) | DOP2012000171A (es) |
EA (1) | EA020865B1 (es) |
EC (1) | ECSP12011992A (es) |
ES (1) | ES2434315T3 (es) |
IL (1) | IL219967A0 (es) |
MA (1) | MA33910B1 (es) |
MX (1) | MX2012006441A (es) |
NZ (1) | NZ600157A (es) |
PE (1) | PE20121481A1 (es) |
SG (1) | SG181436A1 (es) |
TN (1) | TN2012000255A1 (es) |
TW (1) | TW201125575A (es) |
UY (1) | UY33127A (es) |
WO (1) | WO2011078394A2 (es) |
ZA (1) | ZA201203775B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201204378A (en) * | 2010-06-25 | 2012-02-01 | Takeda Pharmaceutical | Sustained-release formulation |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
TWI778979B (zh) | 2016-09-30 | 2022-10-01 | 瑞士商麥歐文科學有限公司 | 治療女性不孕症之方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
AU4477001A (en) * | 2000-04-18 | 2001-10-30 | Peptron Inc. | Injectable sustained release pharmaceutical composition and processes for preparing the same |
AR023940A1 (es) * | 2000-05-03 | 2002-09-04 | Eriochem Sa | Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua |
EP1317304B1 (en) * | 2000-09-01 | 2011-04-27 | Palmaya Pty Ltd. | Slow release pharmaceutical preparation and method of administering same |
US7090869B2 (en) * | 2000-12-01 | 2006-08-15 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
JP2003002841A (ja) * | 2001-04-20 | 2003-01-08 | Takeda Chem Ind Ltd | ペプチド含有製剤 |
WO2002085399A1 (en) * | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Peptide-containing preparations |
US20060241051A1 (en) * | 2002-12-26 | 2006-10-26 | Chieko Kitada | Metastin derivatives and use thereof |
BRPI0512397A (pt) | 2004-06-25 | 2008-03-04 | Takeda Pharmaceutical | composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual |
TW200613012A (en) * | 2004-07-02 | 2006-05-01 | Takeda Pharmaceuticals Co | Sustained-release composition, process for producing the same and use of the same |
CN1923284A (zh) * | 2005-08-30 | 2007-03-07 | 孔庆忠 | 抗癌药物缓释注射剂及其应用 |
ZA200805393B (en) * | 2005-12-22 | 2009-12-30 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
TWI386417B (zh) * | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2008075762A1 (en) * | 2006-12-18 | 2008-06-26 | Takeda Pharmaceutical Company Limited | Sustained-release composition and method for producing the same |
US20110118172A1 (en) * | 2008-04-24 | 2011-05-19 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
MX2011006170A (es) * | 2008-12-29 | 2011-06-27 | Takeda Pharmaceutical | Agente preventivo/terapeutico contra el cancer. |
SI2603600T1 (sl) * | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
-
2010
- 2010-12-21 MX MX2012006441A patent/MX2012006441A/es unknown
- 2010-12-21 KR KR1020127019082A patent/KR20120098906A/ko not_active Application Discontinuation
- 2010-12-21 ES ES10805747T patent/ES2434315T3/es active Active
- 2010-12-21 UY UY33127A patent/UY33127A/es not_active Application Discontinuation
- 2010-12-21 US US13/517,202 patent/US20120302508A1/en not_active Abandoned
- 2010-12-21 JP JP2012528582A patent/JP2013514968A/ja active Pending
- 2010-12-21 WO PCT/JP2010/073665 patent/WO2011078394A2/en active Application Filing
- 2010-12-21 NZ NZ600157A patent/NZ600157A/xx not_active IP Right Cessation
- 2010-12-21 TW TW099144892A patent/TW201125575A/zh unknown
- 2010-12-21 SG SG2012037768A patent/SG181436A1/en unknown
- 2010-12-21 AU AU2010336168A patent/AU2010336168A1/en not_active Abandoned
- 2010-12-21 EP EP10805747.2A patent/EP2515878B1/en active Active
- 2010-12-21 EA EA201290372A patent/EA020865B1/ru not_active IP Right Cessation
- 2010-12-21 BR BR112012014947A patent/BR112012014947A2/pt not_active IP Right Cessation
- 2010-12-21 CA CA2785021A patent/CA2785021C/en active Active
- 2010-12-21 AR ARP100104811A patent/AR079657A1/es not_active Application Discontinuation
- 2010-12-21 PE PE2012000862A patent/PE20121481A1/es not_active Application Discontinuation
- 2010-12-21 CN CN201610917016.8A patent/CN107412725A/zh active Pending
- 2010-12-21 CN CN2010800587326A patent/CN102665690A/zh active Pending
- 2010-12-21 MA MA35045A patent/MA33910B1/fr unknown
-
2012
- 2012-05-23 ZA ZA2012/03775A patent/ZA201203775B/en unknown
- 2012-05-24 TN TNP2012000255A patent/TN2012000255A1/en unknown
- 2012-05-24 IL IL219967A patent/IL219967A0/en unknown
- 2012-05-30 CR CR20120290A patent/CR20120290A/es not_active Application Discontinuation
- 2012-06-18 DO DO2012000171A patent/DOP2012000171A/es unknown
- 2012-06-21 EC ECSP12011992 patent/ECSP12011992A/es unknown
- 2012-06-22 CO CO12104834A patent/CO6551752A2/es unknown
-
2015
- 2015-08-24 JP JP2015164390A patent/JP6472730B2/ja active Active
-
2017
- 2017-03-21 JP JP2017054363A patent/JP2017160201A/ja not_active Withdrawn
- 2017-11-10 US US15/809,459 patent/US20180228732A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24573B1 (es) | Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas | |
GT201200332A (es) | Composiciones sòlidas | |
EA201290482A1 (ru) | Стабильные составы для лиофилизации терапевтических частиц | |
EA201201648A1 (ru) | Стимуляторы sgc | |
EA201201321A1 (ru) | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний | |
MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
NZ629996A (en) | 2’- substituted carba-nucleoside analogs for antiviral treatment | |
EA201270216A1 (ru) | Фармацевтический состав | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
MX367131B (es) | Sales de xantilio 3,6-disustituidas. | |
CR20110209A (es) | Composición farmacéutica sólida | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
MX355330B (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
EA201792597A2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
PE20130728A1 (es) | Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina | |
GB2539148A (en) | Vaccine compositions | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
BR112012013918A2 (pt) | inibidores de diacil glicerol acil transferase | |
PE20121481A1 (es) | Formulacion de liberacion sostenida | |
ECSP11010856A (es) | Composición farmacéutica sólida | |
BR112015001006A2 (pt) | composições farmacêuticas contendo ácido lático oligomérico | |
BR112013001462B8 (pt) | Composições | |
UY32408A (es) | Macrolido anti-inflamatorio | |
NZ603783A (en) | Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |